Market Overview

Morgan Stanley Buys Into Sarepta Amid Sell-Off, Sees $600M Recurring Opportunity In DMD Candidate

Morgan Stanley Buys Into Sarepta Amid Sell-Off, Sees $600M Recurring Opportunity In DMD Candidate

A manufacturing-related hold on Sarepta Therapeutics Inc (NASDAQ: SRPT)’s Duchenne muscular dystrophy candidate catalyzed a recent sell-off. Morgan Stanley sees a buying opportunity in the otherwise-lauded program’s stumble. 

The Analyst

Analyst Matthew Harrison upgraded Sarepta from Equal-weight to Overweight and maintained their $163 price target.

The Thesis

Sarepta has fallen 25 percent off its mid-June, post-data high, but Morgan Stanley is dismissing the pullback.

“We believe the decline has occurred as shareholders transition from mostly short-term to more longer-term oriented investors,” Harrison said in a Wednesday note. (See the analyst's track record here.) 

“Importantly, we do not believe a major bear case has emerged on the prospects for their DMD gene-therapy program.”

A hold on Sarepta’s Phase 1/2 trial is expected to be resolved without delaying a pivotal trial planned to start by the end of the year. Morgan Stanley anticipates drug approval in 2021, but notes that the Food and Drug Administration could accelerate the push to market.

Sarepta’s candidate is seen to lead rivals from Solid Biosciences Inc (NASDAQ: SLDB) and Pfizer Inc. (NYSE: PFE) in both efficacy and timing. Its $600-million recurring market opportunity, which presents a revenue stream that could double Sarepta’s market cap, is not reflected in its valuation, Harrison said. 

“While competition and manufacturing could present headwinds, we believe management will solve any manufacturing hurdles quickly and believe management's lead on competition significantly reduces the competitive threat,” the analyst said. 

New data for the recently acquired limb girdle muscular dystrophy program could also drive upside, according to Morgan Stanley. 

Price Action

Sarepta shares were trading up nearly 7 percent at $124.36 at the time of publication Wednesday. 

Related Links:

Analyst: Solid Biosciences A Solid Buy On Sarepta's Progress

Analyst: Sarepta's DMD Gene Therapy Results 'Dramatic And Far Exceeding Expectations'


Related Articles (PFE + SLDB)

View Comments and Join the Discussion!

Posted-In: David Lebowitz Matthew HarrisonAnalyst Color Biotech Upgrades Price Target Analyst Ratings General Best of Benzinga

Latest Ratings

UBERRBC CapitalMaintains50.0
WIXJMP SecuritiesMaintains363.0
CVIJP MorganInitiates Coverage On22.0
View the Latest Analytics Ratings
Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at